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INTRODUCTION
The Transforming Growth Factor- cytokine superfamily, including TGF, activin, inhibins, nodal and bone morphogenetic proteins (BMPs), regulate developmental and cellular biology to control and maintain tissue homeostasis. In different contexts, the interaction of the dimeric ligands with their cognate receptors activate intracellular signalling pathways to control cell death, survival, adhesion, differentiation, movement and deposition of components of the extracellular matrix (Shi and Massague, 2003) . In human disease the expression of, or cellular responses to, these factors may become deregulated. The resulting aberrant signalling can contribute to many disease pathologies including cancer, fibrosis, atherosclerosis and scarring (Blobe et al., 2000) . TGF, for example, can switch from tumour suppressor to tumour promoter functions depending on epigenetic/genetic changes occurring in the tumour cell (Inman, 2011) . Given their extensive role in human disease, the ligands, their receptors and their downstream effectors are considered attractive therapeutic targets (Akhurst and Hata, 2012) .
Cytokine signalling is initiated by the formation of heterotetrameric complexes of six polypeptides comprising dimeric ligands, two constitutively active type 2 receptors and two type 1 receptors. Upon complex formation, the serine/threonine kinase type 1 receptors are phosphorylated and activated by the type 2 receptors which initiates a canonical signalling cascade involving the recruitment, phosphorylation and activation of receptor-regulated SMADs. The phosphorylated SMADs bind to SMAD4 and the complexes accumulate in the cell nucleus where they both positively and negatively regulate gene expression. In addition, a number of SMAD-independent non-canonical signalling pathways (e.g. mitogen-activated protein kinases, Rho GTPases and phosphoinostide-3-kinases) are also activated which impact on gene regulation and cellular responses (Zhang, 2009) . Five type 2 and seven type 1 receptors have been identified in mammalian cells. Their specificity for ligand and receptor complex formation determines biological outcome (Schmierer and Hill, 2007) . For instance, TGF interacts primarily with TGFBR2 and the ubiquitous type 1 receptor TGFBR1 to regulate cytostasis, apoptosis and epithelial to mesenchymal transition (EMT), but both TGF and GDF2 (BMP9) may bind to the endothelial cell restricted type 1 receptor ACVRL1 to regulate angiogenesis. In some circumstances, TGFβ may also signal via TGFBR1 and ALK2 to induce SMAD1/5 phosphorylation This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on November 20, 2018 as DOI: 10.1124 at ASPET Journals on November 28, 2018 molpharm.aspetjournals.org Downloaded from and a subset of TGFβ-inducible genes involved in EMT (Ramachandran et al., 2018) . BMPs, meanwhile, bind selectively to BMPR2 and the type 1 receptors activin A receptor type 1L (ALK1), activin A receptor type 1 (ALK2), bone morphogenetic protein receptor type 1A (BMPR1A), and bone morphogenetic protein receptor type 1B (BMPR1B) to regulate embryogenesis and bone formation (Wang et al., 2014) . TGF, Activin and Nodal signal via TGFBR1, ALK4 and ALK7, respectively, predominantly to phosphorylate and activate SMAD2 and SMAD3 while BMPs induce phosphorylation of SMAD1, SMAD5 and SMAD8.
Given the role of TGF in pathological states, there have been numerous therapeutic approaches taken to blockade signalling with some progressing through preclinical evaluation to clinical trial (Akhurst and Hata, 2012; Lahn et al., 2005) . Some selective small molecule inhibitors (SMI) of the TGFBR1 kinase are well characterised (e.g. SB-431542) (Inman et al., 2002; Vogt et al., 2011) and have been used extensively in preclinical models to interrogate TGF-regulated biological pathways. SMIs of TGFBR1 have shown therapeutic promise in models of fibrosis (Gellibert et al., 2006; Park et al., 2015a; Park et al., 2015b) , and two TGFBR1 inhibitors are currently in clinical trials, vactosertib and galunisertib (LY2157299). The results of the first in human trials with vactosertib (ClinicalTrials.gov Identifier: NCT02160106) are not yet reported. Galunisertib, however, has progressed despite some initial toxicity concerns, and is now considered safe enough when administered with careful dosing schedules (Fujiwara et al., 2015; Herbertz et al., 2015; Kovacs et al., 2015) , to allow further clinical development in cancer patients with unmet need. TGFBR1 inhibitors therefore remain attractive leads for drug development. AZ12601011 (structure previously undisclosed) and AZ12799734 (Anderton et al., 2011; Goldberg et al., 2009 ) are two selective TGFBR1 inhibitors. AZ12601011 and AZ12799734 inhibit TGFBR1 kinase activity (competition binding) with Kd values of 2.9nM and 740nM, respectively. Both compounds have some inhibitory activity against the related receptors ALK4 and BMPR1B, but are only weakly active against ALK1, ALK2 and BMPR1A in in vitro kinase assays (Anderton et al., 2011) . Here, we characterise their specificity and in vitro and in vivo biological activity in a variety of cell-based biochemical and functional assays, in comparison with other well studied and clinically relevant MOL#112946 6 TGFBR1 SMIs. We show that AZ12601011 is a selective inhibitor of ALK4, ALK7 and TGFBR1.
Importantly, AZ12601011 inhibited TGF-induced epithelial cell migration at 10-fold lower concentrations than galunisertib and was effective in an in vivo tumour model system. Additionally, we identify AZ12799734 as a pan BMP/TGF inhibitor providing a novel spectrum of single agent inhibitory activity useful for analytical evaluation of TGF superfamily regulated processes.
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MATERIALS AND METHODS
Synthetic procedures for AZ12799734 have been described previously (Compound 19, (Goldberg et al., 2009) Synthetic procedures for AZ12601011:
2-Pyridin-2-yl-1,5,6,7-tetrahydrocyclopenta[e]pyrimidin-4-one2-Amidinopyridine hydrochloride (7.88 g, 50 mmol) and K 2 CO 3 (6.91 g, 50 mmol) were added to methyl 2-oxocyclopentanecarboxylate (commercially sourced) (6.21 mL, 50 mmol) in ethanol (100 mL). The mixture was heated to reflux for 5 hours. While the mixture was still hot, it was acidified by the addition of 2 M aq. HCl (20 mL), and water (30 mL). The mixture was allowed to cool to room temperature overnight and was then was partially concentrated in vacuo. The resulting precipitate was collected by filtration, washed with water and diethyl ether and dried in vacuo to give the desired product. Additional product was obtained by concentrating the filtrate in vacuo and purifying the resulting residue by recrystallisation from ethanol/water. The two batches were combined to afford the title compound (3.63 g, 34% 
Plasmids
Plasmids expressing SMAD1 and SMAD2 and constitutively active ALK1, ALK2, BMPR1A, ALK4, TGFBR1, BMPR1B and ALK7 used in transient transfections have been described previously (Inman et al., 2002) .
This article has not been copyedited and formatted. The final version may differ from this version. (Davis, 2000) . Epidermal growth factor (EGF) treatment was carried out by exogenous addition of 30ng/mL EGF for 5 minutes. The MEK1/2 inhibitor U0126 (Tocris) was used at a concentration of 25M.
C2C12-BRE luciferase and NIH3T3-CAGA 12 luciferase reporter bioassays
The C2C12-BRE-luciferase (Herrera and Inman, 2009 ) and NIH3T3-CAGA12-luciferase stable cell lines (Spender et al., 2016) used in the bioassays have been described previously. Cells were seeded overnight at 1x10 4 /well in 96-well plates. Cells were then pre-treated for 20 minutes with a titration of SB-431542 (Inman et al., 2002) (Tocris), SB-525334 (Sigma), AZ12601011 (Anderton et al., 2011) according to the manufacturer's signal protein normalisation strategy (SPS).
Wound healing assay, IncuCyte Zoom and data analysis
An IncuCyte Zoom live cell imaging microscope (Essen Biosciences) with 10x objective and data management software was used to monitor cell migration in wound healing assays. HaCaT cells were seeded overnight in 100mL growth media at 15000 cells/well in 96-well ImageLock plates (Essen Bioscience). Cells were washed twice in PBS and serum starved for 24 hours in DMEM supplemented
This article has not been copyedited and formatted. The final version may differ from this version. with 0.2% FBS to minimise proliferation which would interfere with migration assays. Uniform wounds were then generated using a Woundmaker, the cells washed twice in PBS, and then pre-treated for 20 minutes with titrations of LY2157299 (galunisertib), SB-431542, AZ12601011 or AZ12799734 in DMEM/0.2% FBS. Cells were then treated with BSA/HCL as a carrier control or TGF (5ng/mL).
Closure of the wound was monitored by IncuCyte Zoom imaging over 4 days. Data presented is the mean ± S.E.M of a minimum of three replicate wells taken from a representative experiment. The mean ± SEM relative wound density were determined according to software processing definitions as recommended by the manufacturer.
In vivo 4T1 syngeneic orthotopic mammary fat-pad model for efficacy and PK/PD
The 4T1 cell line was maintained in RPMI 1640 (Invitrogen) supplemented with 10% FCS (Sigma Aldrich) and M1 (Egg Technologies) with 1% glutamine (Invitrogen) in 7.5% CO 2 at 37°C and were detached using 0.05% trypsin (Invitrogen). Cells were implanted in to mammary fat pad 4 in 30μL This article has not been copyedited and formatted. The final version may differ from this version. 
In vivo pharmacokinetic analysis
Each plasma sample (25 l) was prepared using an appropriate dilution factor and compared against an 11 point standard calibration curve (1-10000 nM) prepared in DMSO and spiked into blank plasma.
Acetonitrile (100 l) was added with the internal standard, followed by centrifugation at 3000 rpm for 10 minutes. Supernatant (50 l) was then diluted in 300 l water and analyzed via UPLC-MS/MS. The
Mass Spectrometer and UPLC parameters are detailed below along with the optimisation parameters.
Mass Specrometer and UPLC system parameters
Mass Spec
Waters Ultima Pt
HPLC system Agilent 1100 HPLC
Column Waters x-bridge C18 50 x 2.1, 3.5u 
Optimization parameters for mass spectrometry analysis
This article has not been copyedited and formatted. The final version may differ from this version. In vivo pharmacodynamic analysis of phospho-SMAD2 using ELISA Mouse total SMAD 2/3 mAB (BD Biosciences Cat 610843l) at 1.25μg/ml in PBS/A was used to coat
Greiner black high-bind 96-well plates with incubation for 1hour at room temperature then inverted and blotted. Blocking buffer with 3% BSA (Sigma A-3912) was added and the incubation/blotting process repeated. 4T1 tumour lysate was prepared at 100μg/well in AP lysis buffer containing fresh protease/ phosphatase inhibitors and then added to the wells for an overnight incubation at 4°C. Following this incubation all wells were washed with TBS/T. A plate was incubated with primary antibody (Rabbit Upstate phospho-SMAD2, #05-953) and a second plate was incubated with primary antibody, Rabbit CST Total SMAD 2/3 (CST 3102). Blocking buffer was used for the antibodies and the plates were incubated for 2hours at RT followed by washing with TBS/T. Anti-rabbit HRP conjugate (CST 7074) was added to the plates and incubated for 1hour followed by a further wash. They were developed with Quantablu using the manufacturer's recommended protocol and read on a Tecan SpectroFluor using excitation 340nm / 465nm emission. 
Compound
Stability and specificity of AZ12601011 and AZ12799734
We next tested the suitability, stability and specificity of AZ12601011 and AZ12799734 as reagents for studying TGFβ family signalling in cell based assays. Neither AZ12601011 nor AZ12799734 showed any reduction in their ability to block CAGA 12 -luciferase reporter activity following up to six rounds of This article has not been copyedited and formatted. The final version may differ from this version. freeze-thawing when used at concentrations selected to inhibit CAGA12 activity by approximately 50%
(20nM and 60nM, respectively) (Fig. 3A ). All four inhibitors tested maintained activity when incubated in tissue culture medium for up to 10 days (Fig. 3B ) and effectively maintained efficacy in in vitro cell culture assays over this time period as assessed by the ability to block TGF-mediated induction of SMAD2 phosphorylation (Fig. 3C ). AZ12601011 and AZ12799734 can therefore be used to effectively block TGFβ signalling in phenotypic assays over a 10 day time course.
Previous drugs designed to target the TGF type 1 receptor, such as SB-431542, effectively inhibit the activity of activin and nodal receptors ALK4 and ALK7 in addition to TGFBR1. Using transient transfection assays, we therefore also assessed the effect of AZ12601011 and AZ12799734 on constitutively active ALK4, ALK7 and TGFBR1 receptors expressed in NIH3T3 CAGA 12 reporter cells. Induction of CAGA 12 -luciferase reporter activity induced by transient transfection of the constitutively active receptors is shown in Fig. 4A . Following transient transfection, cells were treated with a titration of AZ12601011 and AZ12799734 and the effect on CAGA 12 reporter activity monitored (Fig. 4B) . AZ12601011 inhibited the activity of ALK4, ALK7 and TGFBR1 at concentrations between 0.01µM -10M equally. AZ12799734 also inhibited the three constitutively active receptors equally at concentrations ranging from 1M -10M. We next tested the effect of AZ12601011 and AZ12799734 on receptor regulated SMAD phosphorylation by transient transfection of constitutively active receptors into NIH3T3 cells (Fig. 4C) . Phosphorylation of co-transfected SMAD1 and SMAD2
by the active receptors was monitored by western blot. All seven receptors induced phosphorylation of either SMAD1 or SMAD2; as expected, phosphorylation of SMAD1 occurred following transfection of ALK1, BMPR1A and BMPR1B, and phosphorylation of SMAD2 occurred following transfection of ALK4, TGFBR1 and ALK7 (Fig. 4C) . AZ12601011 inhibited phosphorylation of SMAD2 but not SMAD1, suggesting that (like SB-431542) AZ12601011 is a selective inhibitor of ALK4, TGFBR1 and ALK7.
AZ12799734, however, inhibited phosphorylation of both SMAD1 and SMAD2 and is thus likely to be a pan BMP/TGF receptor inhibitor. The effect of AZ12999734 on BMP signalling was confirmed using a bioassay measuring the transcriptional activation of a BMP responsive element luciferase reporter This article has not been copyedited and formatted. The final version may differ from this version. construct (C2C12-BRE-LUC) (Herrera and Inman, 2009 ) after exogenous addition of BMP4, BMP6 or GDF2 (BMP9). As expected, given that there was no effect of AZ12601011 on SMAD1 phosphorylation, we saw no inhibition of BMP-induced activity of C2C12-BRE-LUC in AZ12601011 treated cells (Fig. 5A) . Following treatment by AZ12601011, we observed no inhibition of extracellular signals regulating phosphorylation of ERK (induced by EGF) (Fig5B) or p38 MAPK family members (induced by osmotic shock) (Fig. 5C ). AZ12601011 therefore had no inhibitory off-target effect on the EGF-activated EGFR/MEK/ERK signalling cascade (Bogdan and Klambt, 2001 ) which was efficiently blocked by the MEK1/2 inhibitor, U0126, which was used as a positive control for MEK1/2 inhibition (Fig. 5B ).
AZ12601011 and AZ12999734 inhibit TGF-induced migration.
AZ12601011 and AZ12799734 were assessed in functional wound healing assays using HaCaT epithelial cells that measure a TGF-inducible SMAD4-dependent migration responses (Levy and Hill, 2005) . Confluent monolayers of serum-starved (0.2% FBS) HaCaT cells were uniformly scratched using a Woundmaker (Essen Biosciences), and the resulting wound closure was analysed by real time imaging (Fig. 6 ). Serum starved DMSO control treated cells migrated to close the wound by just over 80% after 80 hours incubation. Following treatment with TGF, however, HaCaT cells migrated faster to close the wound entirely within 36 hours. When cells were pre-treated with different concentrations of SB-431542, galunisertib, AZ12601011 or AZ12799734 prior to TGF addition, we observed dosedependent decreases in TGFβ-induced migration. SB-431542, galunisertib, AZ12601011 and AZ12799734 blocked the increase in migration at concentrations of 500nM, 5000nM, 100nM and 500nM, respectively. At 500nM, AZ12601011 reduced cell migration below baseline, which was only achieved at doses ≥5M of SB-431542 and AZ12799734 (data not shown). AZ12601011 therefore was the most effective inhibitor in the wound healing assay, which inhibited TGF-induced migration at concentrations at least 10-fold lower than galunisertib.
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AZ12601011 inhibits tumour growth and metastasis in vivo.
The selectivity profile of AZ12601011 for ALK4, ALK5 and ALK7 (similar in scope to galunisertib in clinical trials) made it a good representative probe molecule to understand the profile of a TGFBR1
inhibitor in vivo, We tested the pharmacokinetics of both drugs (total and free) in BALB/c mice following administration of 50mg/kg dose (Fig. 7A) , and tested the effect of AZ12601011 on 4T1 cell proliferation in vitro prior to its use in an in vivo assay of preventative treatment of 4T1 syngeneic orthotopic tumour growth. AZ12601011 inhibited 4T1 proliferation with an IC 50 of 400nM ( Figure 7B ).
In the orthotopic in vivo assay, AZ12601011 inhibited signalling measured by a reduction in detection of phosphorylated SMAD2 in tumour cell lysates 1 hour after administration (50mg/kg) (Fig.7C ).
AZ12601011 inhibited 4T1 cells growth in vitro (IC50 = 0.4µM) (Fig.7C ). To assess efficacy in vivo, mice were treated twice daily with vehicle or AZ12601011 (50mg/kg) starting the day after implant of 4T1 cells into mammary fat pads. Tumour growth was monitored over 25 days (Fig. 7D) . The average tumour size in the treated (n=10) group up to day 18 (when 13/13 mice in the control group remained in the study) was significantly inhibited by AZ12601011 (p=0.0001) compared to controls (n=13) (Fig.   7E ). 2/13 mice in the control group had to be sacrificed before the end of the study at days 18 and 23 due to large tumour sizes. No tumours in the treated group exceeded the stipulated size limit and 1/10 mice did not develop a measurable tumour. We noted a significant increase in event-free survival (p=0.002) and in the time taken to develop tumours exceeding 0.5cm 3 (p<0.005) in the treated mice (Fig. 7F) . Importantly, we also found a statistically significant reduction (p = 0.025) in the median lung metastasis score in mice treated with AZ12601011 (median = 1) compared to the control group (median = 4), U = 26, z = -2.267, using an exact sampling distribution for U.
AZ12601011 therefore shows efficacy as a single agent therapy in tumour model systems providing a TGFBR1 inhibitor lead compound for future development.
DISCUSSION
Our data describe the specificity and efficacy of two compounds designed to inhibit TGFBR1 kinase activity (AZ12601011 and AZ12799734) in a number of cell-based assays. We provide evidence that AZ12601011 targets ALK4 and ALK7 as well as TGFBR1, while AZ12799734 is a pan inhibitor of ALK1, ALK2, BMPR1A, ALK4, TGFBR1, BMPR1B and ALK7. Thus, although not directly tested here, we predict that like SB-431542, AZ12601011 will also inhibit activin and nodal signalling through ALK4 and ALK7. AZ127994734, we anticipate, may be useful as a single agent combined inhibitor of TGF and BMP activity.
The efficacy of AZ12601011 and AZ12799734 was also assessed in biological assays of TGF-induced transcription and migration. TGF-induced migration of HaCaT epithelial cells is, in part, reported to involve TGF-mediated activation of a genetic program regulated by the ERK signalling pathway demonstrated by the observation that the MEK/ERK inhibitor U2016 can inhibit this response (Zavadil et al., 2001 ). Since 100nM concentrations of AZ12601011 inhibited migration but had no effect on EGF-induced phosphorylation of ERK or p38 phosphorylation up to concentrations of 10M, we conclude that the effects of the inhibitors on migration are not a result of off target inhibition of MEK/ERK but are likely a result of on-target TGFBR1 inhibition. In these assays, AZ12601011 and AZ12799734 were at least 10-fold more effective in blocking TGF-induced transcription and migration than galunisertib currently in clinical trials. Importantly, AZ12601011 reduced signalling via SMAD2 in vivo and also inhibited tumour growth and metastasis of in an orthotopic murine model of breast cancer, suggesting therapeutic potential.
The development of novel inhibitors of TGFBR1 could provide new therapeutic options in TGF-associated pathologies such as cancer and fibrosis. The clinical use of TGFBR1 inhibitors, however, is not without concerns over patient safety. TGF signalling via TGFBR1 has a role in cardiac development (Sridurongrit et al., 2008) and several heart defects are evident in TGF2 null mice.
Because increased TGF expression is involved in cardiac remodelling in response to numerous stresses (Lim and Zhu, 2006) , TGFBR1 inhibitors are predicted to be of benefit in combating the effects of This article has not been copyedited and formatted. The final version may differ from this version. cardiac remodelling in heart failure. However, administration of AZ12601011 to disease-free wild type mice is associated with cardiac toxicity involving the development of aortic lesions (Anderton et al., 2011) . Questions over these homeostatic functions of TGF have thus delayed development of lead compounds like LY2157299 (galunisertib). Similar effects of galunisertib on small mammals were noted during detailed pre-clinical toxicity testing, but, were ameliorated by lower doses and careful dosing schedules (Herbertz et al., 2015) . These concerns therefore appear to be largely overcome and several cancer related trials of galunisertib as a monotherapy, or in combination with other chemotherapeutics, are ongoing. The efficacy of galunisertib in models of cancer, however, appears limited by tumour environmental factors and anti-tumour growth inhibitory effects are lacking in some xenograft models (Herbertz et al., 2015; Maier et al., 2015) . In hepatocellular cancer cells, galunisertib had minimal effects on proliferation, but inhibited invasion (Serova et al., 2015) . Most of the studies to date have focussed on anti-proliferative and tumour-killing potential in standard assays, and there is growing evidence that these inhibitors may be more effective in cancer models measuring metastasis, immune function and cancer stem cell-like properties (Anido et al., 2010; Maurantonio et al., 2011; Penuelas et al., 2009; Spender et al., 2016) . For example, galunisertib has been shown to inhibit TGFβ induced migration and immune suppression in vitro (Yingling et al., 2018) . In addition, SB-431542 inhibits mutant BRAF melanoma cell migration and stem-cell like properties of anchorage independent growth and clonogenicity at low-cell density. These effects are overcome by increasing cell density leading to the conclusion that the dependence of tumour cells on TGF/TGFBR1 signalling is revealed under conditions of cellular stress. TGFBR1 inhibitors may therefore be most effective in inhibiting micrometastasis seeding or outgrowth, following removal of any clinically apparent tumour mass (Spender et al., 2016) . This conclusion is supported by the inhibitory effect of AZ12601011 on HaCaT cell migration and the formation of 4T1 lung metastasis in our experimental cell based assays. Hence, TGF receptor inhibitors remain candidate therapeutic agents with therapeutic potential, despite the lack of significant tumour killing by galunisertib. Additionally, galunisertib has shown promise in ex vivo models of fibrotic disease (Luangmonkong et al., 2017) . AZ12601011 and AZ12799734 therefore This article has not been copyedited and formatted. The final version may differ from this version. Figure 7
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